Aidea Pharma(SH:688488) Xin Lang Cai Jing·2025-10-30 12:50Core Viewpoint - Eddie Pharmaceutical is an innovative company in the domestic anti-HIV drug sector, focusing on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] Group 1: Business Performance - For Q3 2025, Eddie Pharmaceutical reported revenue of 552 million yuan, ranking 21st among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The company's net profit for the same period was 16.11 million yuan, ranking 22nd in the industry, with the top performer, Tonghua Dongbao, achieving a net profit of 1.188 billion yuan [2] - The main business composition includes human-derived proteins at 149 million yuan (41.11%), new drugs at 129 million yuan (35.69%), diagnostic equipment and reagents at 49.35 million yuan (13.62%), and generic drugs at 34.31 million yuan (9.47%) [2] Group 2: Financial Ratios - As of Q3 2025, Eddie Pharmaceutical's debt-to-asset ratio was 41.35%, higher than the previous year's 40.23% and above the industry average of 26.88% [3] - The gross profit margin for the same period was 65.72%, an increase from 52.81% year-on-year, but still below the industry average of 70.17% [3] Group 3: Executive Compensation - The chairman, Fu Helian, received a salary of 1.1336 million yuan in 2024, an increase of 13,900 yuan from 2023 [4] - The president, Zhang Jie, earned 3.7593 million yuan in 2024, up by 745,800 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.55% to 12,100, with an average holding of 34,700 circulating A-shares, a decrease of 1.53% [5] - New significant shareholders include Xingquan Commercial Model Mixed A and Huatai-PineBridge Healthcare Mixed, while some previous top shareholders have exited [5] Group 5: Growth Prospects - In the first half of 2025, Eddie Pharmaceutical's revenue grew by 100.19% year-on-year to 362 million yuan, with a net profit of 9.19 million yuan, marking a turnaround from losses [6][7] - Key growth drivers include the recovery of sales from the already launched product, Ainomi, and the expansion of the HIV drug business [6] - The company is advancing its research on the ACC017 enzyme inhibitor and plans to submit IND applications for long-acting HIV prevention drugs by the end of 2025 [6][7]